684 studies found for:    Open Studies | "Vaccines"
Show Display Options
Rank Status Study
21 Unknown  Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil
Condition: HPV Vaccines
Intervention: Behavioral: SMS Text Message
22 Recruiting A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
Condition: Meningococcal Vaccine
Interventions: Biological: rLP2086;   Biological: Havrix (HAV);   Biological: Saline
23 Recruiting Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants
Condition: Evaluation of a Rotavirus Vaccine
Interventions: Biological: P2VP8 Subunit Vaccine 10mcg;   Biological: P2VP8 Subunit Vaccine 30 mcg;   Biological: P2VP8 Subunit Vaccine 60mcg;   Biological: Placebo;   Biological: Cohort B2 P2VP8 D1;   Biological: Cohort B2 P2VP8 D2
24 Unknown  Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule
Condition: Human Papillomavirus (HPV) Vaccine
Intervention: Biological: HPV-16/18 L1 VLP AS04 vaccine
25 Recruiting Immune Responses to Yellow Fever Vaccine
Condition: Prior Receipt of Yellow Fever Vaccine
Intervention:
26 Not yet recruiting Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
Condition: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions: Biological: 13-valent pneumococcal conjugate vaccine;   Biological: Seasonal Inactivated Influenza Vaccine;   Other: Placebo
27 Unknown  "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency
Condition: Common Variable Immunodeficiency
Interventions: Biological: PPS;   Biological: PnCJ PPS
28 Unknown  Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs
Condition: Vaccine Response Impaired
Intervention: Biological: hepatitis A vaccine
29 Recruiting DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
Conditions: Diphtheria;   Tetanus;   Pertussis;   Haemophilus Influenzae Type b Infection;   Poliomyelitis;   Hepatitis B
Interventions: Biological: DTaP-IPV-Hep B-PRP~T combined vaccine;   Biological: DTaP-IPV//PRP~T and Hepatitis B vaccine
30 Recruiting Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
Conditions: Adult;   Shingles;   Herpes Zoster
Interventions: Biological: Zostavax;   Biological: HZ/su vaccine;   Biological: Placebo
31 Not yet recruiting Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
32 Recruiting The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age
Conditions: Mortality;   Vaccines
Intervention: Biological: Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine
33 Not yet recruiting Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Condition: Meningococcal Disease
Interventions: Biological: Meningoccal B recombinant vaccine together with routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age);   Biological: Routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)
34 Recruiting A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.
Conditions: Smoking;   Vaccines
Interventions: Biological: NIC7-001;   Biological: NIC7-003;   Biological: Saline
35 Recruiting Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
Conditions: Cancer;   Influenza Viral Infections
Interventions: Biological: Standard Trivalent Influenza Vaccine;   Biological: High-Dose Influenza Vaccine
36 Recruiting Systems Biology of 23-valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)
Condition: Pneumococcal Infection
Interventions: Biological: PNEUMOVAX and PREVNAR;   Biological: Pneumovax or Prevnar
37 Recruiting Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults
Conditions: Malaria;   Plasmodium Falciparum Malaria
Interventions: Biological: PfSPZ Vaccine;   Biological: Normal Saline (Placebo)
38 Recruiting Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
Condition: Infections, Meningococcal
Interventions: Biological: Meningococcal vaccine GSK134612;   Biological: Prevenar 13™
39 Recruiting A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Condition: Pneumococcal Infection
Intervention: Biological: Prevnar 13 (PVC13)
40 Recruiting Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults
Condition: Poliomyelitis
Interventions: Biological: a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD);   Biological: a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years